Thiocolchicoside - CAS 602-41-5
Catalog number: B0084-464811
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C27H33NO10S
Molecular Weight:
563.618
COA:
Inquire
Targets:
GABA Receptor
Description:
Thiocolchicoside is a semi-synthetic derivative of colchicine, an anti-inflammatory glycoside extracted from the flower seeds of superba gloriosa. Thiocolchicoside acts as a GABAA receptor antagonist exhibiting anti-inflammatory and analgesic activity. It is used as a muscle relaxant.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-464811 500 mg $199 In stock
B0084-464811 1 g $299 In stock
Bulk Inquiry
Brife Description:
GABAA receptor antagonist
Purity:
>98%
Appearance:
Yellow Solid
Synonyms:
N-[(7S)-3-(β-D-Glucopyranosyloxy)-5,6,7,9-tetrahydro-1,2-dimethoxy-10-(methylthio)-9-oxobenzo[a]heptalen-7-yl]acetamide; (S)-N-[3-(β-D-Glucopyranosyloxy)-5,6,7,9-tetrahydro-1,2-dimethoxy-10-(methylthio)-9-oxobenzo[a]heptalen-7-yl]acetamide; Coltramyl; Coltrax; Miorel; Miotens; Muscoril
Storage:
Store at -20°C
MSDS:
Inquire
Melting Point:
>197°C (dec.)
InChIKey:
LEQAKWQJCITZNK-AXHKHJLKSA-N
InChI:
InChI=1S/C27H33NO10S/c1-12(30)28-16-7-5-13-9-18(37-27-24(34)23(33)22(32)19(11-29)38-27)25(35-2)26(36-3)21(13)14-6-8-20(39-4)17(31)10-15(14)16/h6,8-10,16,19,22-24,27,29,32-34H,5,7,11H2,1-4H3,(H,28,30)/t16-,19+,22+,23-,24+,27+/m0/s1
Canonical SMILES:
CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)OC4C(C(C(C(O4)CO)O)O)O
1.Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database.
Pageot C;Bezin J;Smith A;Arnaud M;Salvo F;Haramburu F;Bégaud B;Pariente A;French Network of Pharmacovigilance Centres Drug Saf. 2017 Nov;40(11):1099-1107. doi: 10.1007/s40264-017-0561-y.
INTRODUCTION: ;The consequences of the withdrawal of marketing authorisation of drugs have mostly been studied considering drug prescription patterns for the therapeutic alternatives of the withdrawn drugs. The potential concomitant changes in the reporting of adverse reactions concerning these alternatives have been studied less often.;OBJECTIVE: ;The objective of this study was to analyse the changes in the reporting of adverse events (AEs) for therapeutic alternatives after the withdrawal of three medicines (dextropropoxyphene, pioglitazone and tetrazepam) from the market for safety reasons.;METHODS: ;This study was performed using both the French pharmacovigilance database and the Echantillon Généraliste des Bénéficiaires (a random sample of French health insurance affiliates). For dextropropoxyphene, pioglitazone and tetrazepam alternatives, the number and types of case reports were studied for both the year preceding the first official safety warning and the year following the withdrawal. Reporting rates expressed per 10,000 reimbursements (RR;Reimb;) and per 10,000 treated patients (RR;Pat;) were also compared for the two periods.;RESULTS: ;After dextropropoxyphene withdrawal, case reports and reimbursements increased for tramadol (case reports: +23%, reimbursements: +13%) and codeine (case reports: +74%, reimbursements: +47%), RR;Pat; being significantly increased for tramadol (0.
2.Safety of subcutaneous microinjections (mesotherapy) in musicians.
Navarte DA;Rosset-Llobet J Med Probl Perform Art. 2011 Jun;26(2):79-83.
OBJECTIVE: ;Determine the safety and tolerance of mesotherapy as a technique for the treatment of musculoskeletal complaints in musicians.;METHOD: ;67 patients (55.2% women) were subjected to a total of 267 mesotherapy sessions. A mesotherapy needle or normal needle was used randomly. The drugs employed were thiocolchicoside and diazepam as muscular relaxants, pentoxifylline or buflomedil as vasodilators, and piroxicam as an anti-inflammatory, as directed. A visual analogue scale was used to quantify the pain produced by the microinjections as well as the degree of immediate and midterm side effects as reported on a standard questionnaire.;RESULTS: ;A mean of 155.5 microinjections were performed per session, of which 45.6% were perceived as painful by the patient with a mean severity of 4.3 out of 10. The pain reduced to 0.5 out of 10 after 24 hours. The most sensitive areas were the levator scapulae and splenius muscles. Systemic symptoms were reported by 5.99% of the musicians after the mesotherapy sessions (muscular weakness 1.5%, rash 1.5%, drowsiness 1.1% and itching 1.1%, being the most frequent). The mean severity of these symptoms was 2.77 out of 10. In all cases the symptoms had completely disappeared after 24 hours.
3.Evaluation of the Effect of Mesotherapy in the Management of Osteoarthritis-Related Pain in a Police Working Dog Using the Canine Brief Pain Inventory.
Alves JC;Santos AM Top Companion Anim Med. 2017 Mar;32(1):41-43. doi: 10.1053/j.tcam.2017.07.002. Epub 2017 Jul 5.
CASE DESCRIPTON: ;A 9-year-old, 33.4kg (73.63Lb) male entire drug detection Labrador Retriever Dog was presented with an history of constant lameness from the right thoracic limb, aggravated with exercise and work.;CLINICAL FIDINGS: ;Clinical examination revealed mild signs of pain on the manipulation of the elbow joint, with reduced range of motion on the end feel of joint flexion and extension and crepitation. Radiographic examination of the right elbow joint revealed severe, chronic osteoarthritis, with osteophyte formation on the humeral epicondyles and articular margin of the distomedial humerus, with a narrowed joint space, and osteophytes on the proximal radius, proximomedial ulna, and anconeal process.;TREATMENT AND OUTCOME: ;A solution comprised of a combination of lidocaine, thiocolchicoside, and piroxicam was prepared and applied around the right elbow joint. The animal was rested for 3 days and normal work load was introduced over a 5-day period. The CPBI was completed by the trainer before treatment (T0), 14 days (T1), 1 (T2), 2 (T3), 3 (T4), 4 (T5), 5 (T6), and 6 (T7) months after treatment. Following the mesotherapy session, pain score results consistently declined until the 3-month evaluation moment.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related GABA Receptor Products


CAS 96604-21-6 Ocinaplon

Ocinaplon
(CAS: 96604-21-6)

Ocinaplon is a GABAA receptor modulator and it can be used for the treatment of generalized anxiety disorder.

CAS 62666-20-0 Progabide

Progabide
(CAS: 62666-20-0)

Progabide is a gamma-aminobutyric acid (GABA) antagonist. It has agonistic activity for both the GABAA and GABAB receptors. It has antiepileptic activity and is...

CAS 3569-10-6 Valerenic acid

Valerenic acid
(CAS: 3569-10-6)

Valerenic acid is a positive allosteric modulator of GABAA receptors displaying selectivity for receptors containing β2 or β3 subunits. Valerenic acid exhibits ...

CAS 78755-81-4 Flumazenil

Flumazenil
(CAS: 78755-81-4)

Flumazenil is a GABAA receptor antagonist and the only GABAA receptor antagonist on the market today.

CAS 57717-80-3 CGP7930

CGP7930
(CAS: 57717-80-3)

CGP7930 is a positive allosteric modulator at the GABAB receptor. It has anxiolytic effects in animal studies, and has a synergistic effect with GABAB agonists ...

CAS 21967-41-9 Baicalin

Baicalin
(CAS: 21967-41-9)

Baicalin is a flavone found in several species in the genus Scutellaria, including Scutellaria baicalensis and Scutellaria lateriflora. Baicalin is a positive a...

CAS 157604-55-2 (S)-SNAP 5114

(S)-SNAP 5114
(CAS: 157604-55-2)

(S)-SNAP 5114 is a GABA transport inhibitor, displaying selectivity for GAT-3 and GAT-2 (IC50 = 5, 21 and 388 μM for hGAT-3, rGAT-2 and hGAT-1, respectively). (...

CAS 1135210-68-2 Tracazolate hydrochloride

Tracazolate hydrochloride
(CAS: 1135210-68-2)

Tracazolate hydrochloride is a subtype-selective GABAA receptor modulator that potentiates or inhibits recombinant GABAA function depending on subunit combinati...

Chemical Structure

CAS 602-41-5 Thiocolchicoside

Quick Inquiry

Verification code

Featured Items